Significance of optimal therapy for ulcerative colitis patients with clinical remission who have colonic active lesions
Not Applicable
- Conditions
- lcerative colitis
- Registration Number
- JPRN-UMIN000018075
- Lead Sponsor
- Center for Diagnostic and Therapeutic Endoscopy,Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who can not distinct from other colitis, such as infectious colitis. Patients who have any gastrointestinal stenosis. Patients who were changed the dose of 5-ASA, or who received topical enema, or adalimumab within 2 weeks before the entry of study, or who received infliximab within 4 weeks before the entry of study. Patients who received corticosteroids within 4 weeks before the entry of study. Patients who received thiopurine, or tacrolimus, or cyclosporin within 8 weeks before the entry of study. Patients who receive apheresis within 2 weeks before the entry of study. Patients who will have plans to receive surgical treatments within 12 months after the entry of study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of clinical maintenance of remission within 12 months after entry of the study
- Secondary Outcome Measures
Name Time Method